Oncotarget

Research Papers:

ERα propelled aberrant global DNA hypermethylation by activating the DNMT1 gene to enhance anticancer drug resistance in human breast cancer cells

Xinxin Si, Yue Liu, Jinghuan Lv, Haijian Ding, Xin A. Zhang, Lipei Shao, Nan Yang, He Cheng, Luan Sun, Dongliang Zhu, Yin Yang, Andi Li, Xiao Han and Yujie Sun _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:20966-20980. https://doi.org/10.18632/oncotarget.8038

Metrics: PDF 1936 views  |   HTML 2754 views  |   ?  


Abstract

Xinxin Si1,5,*, Yue Liu1,5,*, Jinghuan Lv6, Haijian Ding1,5, Xin A. Zhang4, Lipei Shao1,5, Nan Yang1, He Cheng1,5, Luan Sun1,5, Dongliang Zhu5, Yin Yang1,5, Andi Li1,5, Xiao Han1, Yujie Sun1,2,3,5

1Key Laboratory of Human Functional Genomics of Jiangsu Province, Nanjing Medical University, Nanjing, Jiangsu, China

2Collaborative Innovation Center for Cancer Medicine, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Nanjing Medical University, Nanjing, Jiangsu, China

3State Key Laboratory of Reproductive Medicine, Nanjing Medical University, Nanjing, Jiangsu, China

4Department of Physiology and Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA

5Department of Cell Biology, Nanjing Medical University, Nanjing, Jiangsu, China

6Department of Pathology, Municipal Hospital, Suzhou Hospital Affiliated to Nanjing Medical University, Suzhou, Jiangsu, China

*These authors have contributed equally to this work

Correspondence to:

Yujie Sun, e-mail: [email protected]

Keywords: ERα, DNMT1, DNMT3b, global DNA hypermethylation, breast cancer chemoresistance

Received: July 31, 2015    Accepted: February 16, 2016    Published: March 12, 2016

ABSTRACT

Drug-induced aberrant DNA methylation is the first identified epigenetic marker involved in chemotherapy resistance. Understanding how the aberrant DNA methylation is acquired would impact cancer treatment in theory and practice. In this study we systematically investigated whether and how ERα propelled aberrant global DNA hypermethylation in the context of breast cancer drug resistance. Our data demonstrated that anticancer drug paclitaxel (PTX) augmented ERα binding to the DNMT1 and DNMT3b promoters to activate DNMT1 and DNMT3b genes, enhancing the PTX resistance of breast cancer cells. In support of these observations, estrogen enhanced multi-drug resistance of breast cancer cells by up-regulation of DNMT1 and DNMT3b genes. Nevertheless, the aberrant global DNA hypermethylation was dominantly induced by ERα-activated-DNMT1, since DNMT1 over-expression significantly increased global DNA methylation and DNMT1 knockdown reversed the ERα-induced global DNA methylation. Altering DNMT3b expression had no detectable effect on global DNA methylation. Consistently, the expression level of DNMT1 was positively correlated with ERα in 78 breast cancer tissue samples shown by our immunohistochemistry (IHC) analysis and negatively correlated with relapse-free survival (RFS) and distance metastasis-free survival (DMFS) of ERα-positive breast cancer patients. This study provides a new perspective for understanding the mechanism underlying drug-resistance-facilitating aberrant DNA methylation in breast cancer and other estrogen dependent tumors.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8038